Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | SNCA | P37840 | 1/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.44 |
| ▸ | CLK2 | P49760 | 1/20 | 0.43 |
| ▸ | CLK3 | P49761 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | AXL | P30530 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | CHUK | O15111 | 5/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GABRP | O00591 | 1/20 | 0.38 |
| ▸ | GABRD | O14764 | 1/20 | 0.38 |
| ▸ | IKBKB | O14920 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31691908 | 0.83 | DAO (0.53) | DAOMAPTSNCAHRH4CLK2 | |
| SCHEMBL4805509 | 0.83 | DAO (0.53) | DAOMAPTSNCAHRH4CLK2 | |
| SCHEMBL12571647 | 0.79 | DAO (0.49) | DAOMAPTSNCAHRH4CLK2 | |
| SCHEMBL15906825 | 0.77 | DAO (0.65) | DAOMAPTSNCAHRH4CLK2 | |
| SCHEMBL7491546 | 0.75 | DAO (0.53) | DAOMAPTSNCAHRH4CHUK | |
| SCHEMBL7494057 | 0.75 | DAO (0.53) | DAOMAPTSNCAHRH4CLK2 | |
| SCHEMBL7493091 | 0.75 | DAO (0.53) | DAOMAPTSNCAHRH4CLK2 | |
| SCHEMBL27969894 | 0.75 | DAO (0.53) | DAOMAPTSNCAHRH4CLK2 | |
| SCHEMBL22509607 | 0.75 | DAO (0.53) | DAOMAPTSNCAHRH4CLK2 | |
| SCHEMBL24038427 | 0.75 | DAO (0.49) | DAOMAPTSNCAHRH4CLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 232 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114573578-B | Preparation method of alkyl substituted azaindole | 烟台宁远药业有限公司 | 2023-11-17 | — | — | CN | claimed |
| CN-114573578-A | Preparation method of alkyl substituted azaindole | 烟台宁远药业有限公司 | 2022-06-03 | — | — | CN | claimed |
| US-12616682-B2 | 1-H-pyrrolo[2,3-c]pyridine compounds | ACERTA PHARMA B.V. (NL) | 2026-05-05 | — | — | US | disclosed |
| US-20250360112-A1 | 1-H-PYRROLO[2,3-c]PYRIDINE COMPOUNDS | ACERTA PHARMA BV (NL) | 2025-11-27 | — | — | US | disclosed |
| US-20240335431-A1 | 1-H-PYRROLO[2,3-c]PYRIDINE COMPOUNDS | ACERTA PHARMA B.V. (NL) | 2024-10-10 | — | — | US | disclosed |
| US-11958873-B2 | Proteasome activity enhancing compounds | Kineta, Inc. (US) | 2024-04-16 | — | — | US | disclosed |
| CN-114573578-B | Preparation method of alkyl substituted azaindole | 烟台宁远药业有限公司 | 2023-11-17 | — | — | CN | disclosed |
| US-20230312481-A1 | SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF | ARBUTUS BIOPHARMA CORP (CA) | 2023-10-05 | — | — | US | disclosed |
| US-20230312481-A1 | SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF | ARBUTUS BIOPHARMA CORP (CA) | 2023-10-05 | — | — | US | disclosed |
| EP-3555070-B1 | AMINE-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS AND METHODS OF USE THEREOF | EPIZYME INC (US) | 2023-08-09 | — | — | EP | disclosed |
| US-20230242557-A9 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | Kineta, Inc. | 2023-08-03 | — | — | US | disclosed |
| WO-2004108892-A2 | 1,1-DISUBSTITUTEDCYCLOALKYL-, GLYCINAMIDYL-, SULFONYL-AMIDINO-, AND TETRAHYDROPYRIMIDINYL-CONTAINING DIAMINOALKYL, β-AMINOACIDS, α-AMINOACIDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-12-16 | — | — | WO | disclosed |
| WO-2004083174-A2 | SULFONYL-AMIDINO CONTAINING AND TETRAHYDROPYRIMIDINO CONTAINING COMPOUNDS AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-09-30 | — | — | WO | disclosed |
| US-20040116399-A1 | Inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. | 2004-06-17 | — | — | US | disclosed |
| US-20040116399-A1 | Inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. | 2004-06-17 | — | — | US | disclosed |
| WO-2004041776-A2 | SULFONYLAMINOVALEROLAC TAMS AND DERIVATIVES THEREOF AS FACTOR Xa INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-05-21 | — | — | WO | disclosed |
| WO-2003099276-A1 | 1,1-DISUBSTITUTED CYCLOALKYL DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-04 | — | — | WO | disclosed |
| WO-2003047520-A2 | SUBSTITUTED AMINO METHYL FACTOR Xa INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-06-12 | — | — | WO | disclosed |
| WO-2003048081-A2 | GLYCINAMIDES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-06-12 | — | — | WO | disclosed |
| WO-2003026652-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242557-A9 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PSMG3, PSMB1, PSMC1 | DAO 3246/4885MAPT 943/4885SNCA 1101/4885 |
| US-12616682-B2 | 1-H-pyrrolo[2,3-c]pyridine compounds | MEN1, PKD1, PKD2 | DAO 1815/4885MAPT 1547/4885SNCA 597/4885 |
| US-20230312481-A1 | SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF | NSD3, PML, NSD1 | DAO 878/4885MAPT 484/4885SNCA 2524/4885 |
| US-20240335431-A1 | 1-H-PYRROLO[2,3-c]PYRIDINE COMPOUNDS | MEN1, PKD1, ADCYAP1R1 | DAO 3916/4885MAPT 741/4885SNCA 481/4885 |
| US-11958873-B2 | Proteasome activity enhancing compounds | PSMG3, PSMB1, PSMC1 | DAO 3246/4885MAPT 943/4885SNCA 1101/4885 |
| US-20250360112-A1 | 1-H-PYRROLO[2,3-c]PYRIDINE COMPOUNDS | MEN1, PKD1, ADCYAP1R1 | DAO 3916/4885MAPT 741/4885SNCA 481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.